Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

This study has been completed.
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier:
First received: March 11, 2011
Last updated: March 8, 2013
Last verified: March 2013

The purpose of this study is to assess the safety, pharmacokinetics and efficacy of ABT-267 in combination with Peginterferon alpha-2a/Ribavirin (pegIFN/RBV) for 12 weeks in treatment naïve Hepatitis C virus (HCV) genotype 1 infected subjects.

Condition Intervention Phase
Chronic Hepatitis C
Hepatitis C Virus (HCV)
Drug: ABT-267
Drug: Peginterferon alpha-2a (pegIFN)
Drug: Ribavirin (RBV)
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of ABT-267 in Combination With Peginterferon Alpha-2a and Ribavirin (pegIFN/RBV) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Resource links provided by NLM:

Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Assess 4-week rapid virologic response (RVR) [ Time Frame: At Week 4 ] [ Designated as safety issue: No ]
    Assess 4-week rapid virologic response (RVR) of three different doses of ABT-267 in combination with pegIFN/RBV compared to pegIFN/RBV alone (ABT-267 placebo) in HCV genotype 1-infected treatment-naive adults.

Secondary Outcome Measures:
  • Assess percentage of subjects with partial early virologic response (EVR). [ Time Frame: Baseline to Week 12 ] [ Designated as safety issue: No ]
    Assess the percentage of subjects with partial virologic response (EVR).

  • Assess percentage of subjects with complete early virologic response (cEVR). [ Time Frame: At Week 12 ] [ Designated as safety issue: No ]
    Assess percentage of subjects with complete early virologic response (cEVR).

Enrollment: 37
Study Start Date: March 2011
Study Completion Date: February 2013
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1
Low dose ABT-267 + Peginterferon alpha-2a/Ribavirin (pegIFN/RBV)
Drug: ABT-267
Drug: Peginterferon alpha-2a (pegIFN)
injectible solution
Drug: Ribavirin (RBV)
Experimental: Arm 2
Medium dose ABT-267 + pegIFN/RBV
Drug: ABT-267
Drug: Peginterferon alpha-2a (pegIFN)
injectible solution
Drug: Ribavirin (RBV)
Experimental: Arm 3
High dose ABT-267 + pegIFN/RBV
Drug: ABT-267
Drug: Peginterferon alpha-2a (pegIFN)
injectible solution
Drug: Ribavirin (RBV)
Placebo Comparator: Arm 4
Placebo + pegIFN/RBV
Drug: Peginterferon alpha-2a (pegIFN)
injectible solution
Drug: Ribavirin (RBV)
Drug: Placebo


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female, 18-65 years old, inclusive.
  • Treatment naïve.
  • Females must be either postmenopausal for at least 2 years or surgically sterile and males must be surgically sterile or practicing specific forms of birth control.
  • Chronic hepatitis C virus (HCV) genotype-1 infection.
  • Documented FibroTest score in combination with an Aspartate Aminotransferase to Platelet Ratio Index (APRI), or a liver biopsy within the last 12 months to document absence of cirrhosis.

Exclusion Criteria:

  • Pregnant or breastfeeding female.
  • Use of any medications contraindicated for use with Peginterferon alpha-2a (pegIFN) or Ribavirin (RBV) within 2 weeks prior to study drug administration.
  • Clinically significant cardiac, respiratory (except mild asthma), renal, gastrointestinal, hematologic, or neurologic disease, or any uncontrolled medical illness or psychiatric disease or disorder.
  • Current or past clinical evidence of cirrhosis or bridging fibrosis.
  • Abnormal screening laboratory results.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01314261

United States, Alabama
Site Reference ID/Investigator# 56623
Birmingham, Alabama, United States, 35215
United States, California
Site Reference ID/Investigator# 48476
Los Angeles, California, United States, 90048
United States, Florida
Site Reference ID/Investigator# 51345
Orlando, Florida, United States, 32809
United States, Hawaii
Site Reference ID/Investigator# 51498
Honolulu, Hawaii, United States, 96814
United States, Indiana
Site Reference ID/Investigator# 48473
Indianapolis, Indiana, United States, 46202
United States, Missouri
Site Reference ID/Investigator# 52782
Kansas City, Missouri, United States, 64134
United States, Texas
Site Reference ID/Investigator# 48471
Houston, Texas, United States, 77030
Site Reference ID/Investigator# 48474
San Antonio, Texas, United States, 78215
United States, Virginia
Site Reference ID/Investigator# 48477
Fairfax, Virginia, United States, 22031
United States, Washington
Site Reference ID/Investigator# 48472
Seattle, Washington, United States, 98101
Puerto Rico
Site Reference ID/Investigator# 48483
San Juan, Puerto Rico, 00927
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Study Director: Armen Asatryan, MD AbbVie
  More Information

No publications provided

Responsible Party: AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier: NCT01314261     History of Changes
Other Study ID Numbers: M12-114
Study First Received: March 11, 2011
Last Updated: March 8, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Hepatitis, Chronic
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Peginterferon alfa-2a
Anti-Infective Agents
Antiviral Agents
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 19, 2014